EGFR and lung cancer: In 2004, three research groups reported that mutations in the tyrosine kinase domain of EGFR can predict the responses to TKIs in NSCLC patients[12-14], which enables the identification of patient populations that are more likely to benefit from TKI therapies and serves as the first step toward personalizing lung cancer therapy.